Article date: 1979/11/16
PubMed ID: 227532
Journal name: Brain research (ISSN: 0006-8993)
Neurotransmitter receptor binding of 5 ligands was examined in the striatum, substantia nigra (SN) and frontal cortex of rats which had received either unilateral 6-hydroxydopamine (6-OHDA) lesions of the nigrostriatal pathway (NSP) or unilateral kainic acid lesions of the striatum. 6-OHDA lesions of the NSP significantly reduced [3H]dihydroalprenolol ([3H]DHA) and [3H]naloxone ([3H]Nal) binding by 31% and 28% respectively, in the denervated striatum compared to the contralateral side. Scatchard analysis revealed that the alteration in [3H]DHA binding was not due to a change in the affinity of the beta-adrenergic receptor for [3H]DHA. In marked contrast to these changes in the striatum, destruction of the NSP resulted in a significant increase in [3H]DHA and [3H]Nal binding by 44% and 26%, respectively, in the frontal cortex of the lesioned compared to the control side. 6-OHDA lesions in the NSP did not alter striatal receptor binding for [3H]quinuclidinyl benzilate ([3H]QNB), [3H]muscimol ([3H]Mus) or [3H]flunitrazepam ([3H]Flu). Similarily, intrastriatal kainic acid injections did not alter striatal receptor binding for [3H]Nal, [3H]Flu or [3H]Mus. Of the various receptor densities measured in the SN after the above lesions the only alteration observed was a 43% increase in [3H]Flu binding following 6-OHDA lesions of the NSP. Scatchard analysis indicated no change in the affinity of the benzodiazepine receptor for [3H]Flu. 6-OHDA lesions of the NSP did not alter [13H]QNB or [3H]Nal binding in the SN. Striatal kainic acid lesions did not alter nigral [3H]QNB or [3H]Flu binding. The results are discussed in terms of neurotransmitter localization and plasticity within the striatum, SN and frontal cortex.
Author List: Reisine T D, Nagy J I, Beaumont K, Fibiger H C, Yamamura H I
Publication Types: Journal Article; Research Support, U.S. Gov't, P.H.S.
Substances mentioned in the article: Hydroxydopamines; Receptors, Adrenergic, beta; Receptors, Cholinergic; Receptors, Dopamine; Receptors, Neurotransmitter; Receptors, Opioid; Muscimol; Naloxone; gamma-Aminobutyric Acid; Dihydroalprenolol; Quinuclidinyl Benzilate; Fluphenazine; Kainic Acid;
Mesh terms: Animals; Brain Mapping; Corpus Striatum/drug effects; Dihydroalprenolol/metabolism; Fluphenazine/metabolism; Hydroxydopamines/pharmacology; Kainic Acid/pharmacology; Male; Muscimol/metabolism; Naloxone/metabolism; Neural Pathways/drug effects; Neurons/drug effects; Quinuclidinyl Benzilate/metabolism; Rats; Receptors, Adrenergic, beta/metabolism; Receptors, Cholinergic/metabolism; Receptors, Dopamine/drug effects; Receptors, Neurotransmitter/metabolism; Receptors, Opioid/metabolism; Substantia Nigra/drug effects; gamma-Aminobutyric Acid/metabolism;